Monday, March 15, 2010

FDA Announces Review of ACCORD Data - in Meeting Coverage, ACC from MedPage Today

The spokesperson said the agency planned to include a review of the labeling and indications for fenofibric acid (Trilipix). It should, however, be noted that the trial used fenofibrate (TriCor).

Both Trilipix and TriCor are marketed by Abbott, and Trilipix is "the active metabolite of TriCor," according to Marshall Elam, MD, PhD, of the Memphis VA Medical Center.

Posted via web from Jack's posterous

No comments: